Literature DB >> 28681542

Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States.

Ammar Sarwar1, Lujia Zhou1, Victor Novack2, Elliot B Tapper3,4, Michael Curry3, Raza Malik3, Muneeb Ahmed1.   

Abstract

The link between higher procedure volume and better outcomes for surgical procedures is well established. We aimed to determine whether procedure volume affected inpatient mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS). An epidemiological analysis of an all-payer database recording hospitalizations during 2013 in the United States (Nationwide Readmissions Database) was performed. All patients ≥ 18 years old undergoing TIPS during a hospital admission (n = 5529) without concurrent or prior liver transplantation were selected. All-cause inpatient mortality was assessed. Risk-adjusted mortality was assessed for hospitals categorized into quintiles based on annual TIPS volume (very low, 1-4/year; low, 5-9/year; medium, 10-19/year; high, 20-29/year; and very high, ≥ 30/year). TIPS were placed in all 5529 patients (mean age, 57 years [standard deviation, ± 10.9 years]; women, n = 2071; men, n = 3458). Mortality decreased with rising annual TIPS volume (13% for very low to 6% for very high volume hospitals; P < 0.01). Elective admissions were more common in hospitals with higher annual TIPS volume (20.3% for very low to 30.8% for very high; P < 0.01). On multivariate analysis, compared with hospitals performing ≥30 TIPS per year, only hospitals performing 1-4/year (adjusted odds ratio [aOR], 1.9; 95% confidence interval [CI], 1.21-3.01; P = 0.01), 5-9/year (aOR, 2.0; 95% CI, 1.25-3.17; P < 0.01), and 10-19/year (aOR, 1.9; 95% CI, 1.17-3.00; P = 0.01) had higher inpatient mortality (20-29/year: aOR, 1.4; 95% CI, 0.84-2.84; P = 0.19). The absolute difference between risk-adjusted mortality rate for very low volume and very high volume hospitals was 6.1% (13.9% versus 7.8%). TIPS volume of ≤ 20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk factors for inpatient mortality in patients with both elective and emergent admissions.
Conclusion: The risk of inpatient mortality is lower in hospitals performing ≥20 TIPS per year. Future research exploring preventable factors for higher mortality and benefits of patient transfer to higher volume centers is warranted. (Hepatology 2018;67:690-699).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28681542     DOI: 10.1002/hep.29354

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites: A population-based cohort study.

Authors:  Jeffrey M Mah; Maya Djerboua; Patti A Groome; Christopher M Booth; Jennifer A Flemming
Journal:  Can Liver J       Date:  2020-11-17

Review 2.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 3.  The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.

Authors:  Hae Lim Lee; Sung Won Lee
Journal:  Clin Mol Hepatol       Date:  2021-09-27

4.  FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts.

Authors:  Simone Anna Keimburg; Jens Theysohn; Matthias Buechter; Jassin Rashidi-Alavijeh; Katharina Willuweit; Hannah Schneider; Axel Wetter; Benjamin Maasoumy; Christian Lange; Heiner Wedemeyer; Antoaneta Angelova Markova
Journal:  Biomedicines       Date:  2022-04-28

5.  Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.

Authors:  Andrew S Allegretti; Nathan E Frenk; Darrick K Li; Harish Seethapathy; Xavier F Vela Parada; Joshua Long; Paul Endres; Daniel S Pratt; Raymond T Chung; Suvranu Ganguli; Zubin Irani; Kei Yamada
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 6.  Current approaches to the management of patients with cirrhotic ascites.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

7.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

8.  Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Lukas Sturm; Michael Praktiknjo; Dominik Bettinger; Jan P Huber; Lara Volkwein; Arthur Schmidt; Rafael Kaeser; Johannes Chang; Christian Jansen; Carsten Meyer; Daniel Thomas; Robert Thimme; Jonel Trebicka; Michael Schultheiß
Journal:  Hepatol Commun       Date:  2021-01-05

9.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.